Search results for "43"

showing 10 items of 1438 documents

Worsening of Preexisting Psychiatric Conditions During the COVID-19 Pandemic

2020

Objectives: To ascertain factors associated with worsening of psychiatric conditions during the coronavirus disease 2019 (COVID-19) pandemic. Methods: This study anonymously examined 2,734 psychiatric patients worldwide for worsening of their preexisting psychiatric conditions during the COVID-19 pandemic. An independent clinical investigation of 318 psychiatric patients from United States was used for verification. Results: Valid responses mainly from 12 featured countries indicated self-reported worsening of psychiatric conditions in two-thirds of the patients assessed that was through their significantly higher scores on scales for general psychological disturbance, posttraumatic stress …

COVID-19; psychiatric patients; worsening; depression; post traumatic stress disorder; general psychological disturbancemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)lcsh:RC435-571media_common.quotation_subjectPsychological interventionOptimismDose adjustmentlcsh:Psychiatrygeneral psychological disturbancePandemicMedicineworseningPsychiatryDepression (differential diagnoses)media_commonOriginal ResearchPsychiatrypost traumatic stress disorderbusiness.industrypsychiatric patientsCOVID-19Posttraumatic stressPsychiatry and Mental healthFeelingdepressionbusinessFrontiers in Psychiatry
researchProduct

MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.

2008

AbstractUsing a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of CD20. We show that MS4A12 is a cell surface protein. Expression analysis and immunohistochemistry revealed MS4A12 to be a colonic epithelial cell lineage gene confined to the apical membrane of colonocytes with strict transcriptional repression in all other normal tissue types. Expression is maintained upon malignant transformation in 63% of colon cancers. Ca2+ flux analyses disclosed that MS4A12 is a novel component of store-operated Ca2+ entry in intestinal cells. Using RNAi-mediated gene silencing, we show that loss of MS4A12 in LoVo co…

Calcium Channel Blockers/pharmacologyCancer ResearchColorectal cancerColonCalcium Channels/geneticsCell Differentiation/geneticsEpidermal Growth Factor/pharmacologyBiologyRNA Small Interfering/pharmacologyModels BiologicalMalignant transformationEpidermal growth factorCell Line TumormedicineMembrane Proteins/antagonists & inhibitorsHumansGrowth factor receptor inhibitorNeoplasm InvasivenessRNA Small InterferingEpidermal Growth FactorGene Expression ProfilingMembrane ProteinsColonic Neoplasms/geneticsCell DifferentiationApical membranemedicine.diseaseCalcium Channel BlockersColon/metabolismCell biologyChemokines/metabolismProtein Structure TertiaryGene Expression Regulation NeoplasticOncologyCell cultureOrgan SpecificityCancer cellColonic NeoplasmsDisease ProgressionCalcium ChannelsChemokinesA431 cellsCancer research
researchProduct

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome

2021

BackgroundBreast cancer (BC) progression to metastatic disease is the leading cause of death in women worldwide. Metastasis is driven by cancer stem cells (CSCs) and signals from their microenvironment. Interleukin (IL) 30 promotes BC progression, and its expression correlates with disease recurrence and mortality. Whether it acts by regulating BCSCs is unknown and could have significant therapeutic implications.MethodsHuman (h) and murine (m) BCSCs were tested for their production of and response to IL30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array. Immunocompetent mice were used to investigate the role of BCSC-derived IL30 on tumor…

Cancer Research2434ImmunologyTriple Negative Breast NeoplasmsBiologyInterleukin-23Paracrine signallingMiceCancer stem cellCell Line Tumorbreast neoplasmsImmunology and Allergytumor microenvironmentAnimalsHumans1506Autocrine signallingRC254-282PharmacologyTumor microenvironmentbreast neoplasms cytokines tumor microenvironmentInterleukinsInnate lymphoid cellNeoplasms. Tumors. Oncology. Including cancer and carcinogensFOXP3Basic Tumor ImmunologyDendritic cellcytokinesChemokine CXCL10Autocrine CommunicationOncologyKLF4Cancer researchNeoplastic Stem CellsMolecular MedicineFemaleJournal for Immunotherapy of Cancer
researchProduct

Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tum…

2021

Simple Summary Variable domains of heavy chain only antibodies are small proteins that can be used for tumor imaging and therapy upon conjugation of functional groups. As frequently used random conjugation techniques can decrease binding to the target of interest, site-specific conjugation of these functional groups is preferred. Here, we optimized site-specific conjugation of both a chelator for binding of a radiometal and a photosensitizer to epidermal growth factor receptor (EGFR) binding VHH 7D12. We characterized this dual-labeled VHH for nuclear imaging and targeted photodynamic therapy of EGFR-expressing tumors. Abstract Variable domains of heavy chain only antibodies (VHHs) are valu…

Cancer ResearchFluorescence-lifetime imaging microscopyBiodistribution[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedia_common.quotation_subjectmedicine.medical_treatmentPhotodynamic therapyvariable domain of heavy chain only antibodies (VHH); site-specific conjugation; dual-labeling; nuclear imaging; photodynamic therapy[SDV.CAN]Life Sciences [q-bio]/Cancer[CHIM.THER]Chemical Sciences/Medicinal Chemistrylcsh:RC254-282Article030218 nuclear medicine & medical imaging03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterIn vivoduallabelingmedicineTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]PhotosensitizerInternalizationmedia_commonnuclear imagingChemistrysite-specific conjugationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncologyphotodynamic therapy030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]dual-labelingBiophysicsvariable domain of heavy chain only antibodies (VHH)A431 cellsEx vivoCancers
researchProduct

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020

BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.MethodsThis randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.ResultsAt a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 mont…

Cancer Researchmedicine.medical_specialty2435[SDV]Life Sciences [q-bio]ImmunologyMedizinIpilimumabrandomized trialsGastroenterologyAsymptomaticlaw.inventionimmunology03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineClinical endpointImmunology and Allergy1506030212 general & internal medicineAdverse effectRC254-282Clinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryIncidence (epidemiology)MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseimmunology; oncology; randomized trials[SDV] Life Sciences [q-bio]Oncology030220 oncology & carcinogenesisoncologyMolecular Medicinemedicine.symptombusinessBrain metastasismedicine.drug
researchProduct

Interacciones dieta-genotipo entre el consumo de grasas y polimorfismos comunes determinando el metabolismo lipídico

2009

Las recomendaciones dietéticas actuales referentes al consumo de grasas en la dieta han sido realizadas sin tener en cuenta las posibles diferencias genéticas de las personas que podrían ser las responsables de las diferentes respuestas interindividuales que frecuentemente se observan ante la misma dieta. La presencia de variabilidad genética ha sido puesta de manifiesto para todos los genes relacionados con el metabolismo lipídico, por lo que existe un ingente número de genes y de variantes genéticas para ser incluidas en los estudios sobre interacciones dieta-genotipo en el ámbito específico del consumo de grasas y aceites. Se revisarán algunos ejemplos sobre interacciones grasa-genotipo.…

Candidate genemedicine.medical_specialtyInteractionPopulationNutrigenéticalcsh:TX341-641BiologyDieta; Genes; Interacción; Lípidos; Nutrigenética; PolimorfismosLípidosNutrigeneticsInteracciónNutrigenéticaInternal medicineAPOA1 GenemedicineTX341-641PPARA GeneGenetic variabilityeducationNutrigeneticsGeneticseducation.field_of_studyNutrition. Foods and food supplyOrganic ChemistryPolimorfismosLipid metabolism:CIENCIAS MÉDICAS [UNESCO]LipidsDietEndocrinologyNutrigenomicsGenesInteracciónUNESCO::CIENCIAS MÉDICASLípidoslipids (amino acids peptides and proteins)DietaPolymorphismslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

What You Should Know About Carbon Markets

2008

Since the entry into force of the Kyoto Protocol, carbon trading has been in continuous expansion. In this paper, we review the origins of carbon trading in order to understand how carbon trading works in Europe and, specifically, the functioning of the European Union Emission Trading Scheme (EU ETS) and the workings of several spot, futures and options markets where European Union Allowances are traded. As well, the linking of the EU ETS with the other United Nations carbon markets is also studied.

Carbon MarketsControl and OptimizationEnergy Engineering and Power TechnologyEuropean Union Emission Trading Schemelcsh:Technologyjel:Q40Clean Development MechanismEmission TradingOrder (exchange)jel:Qjel:Q43jel:Q42jel:Q41jel:Q48media_common.cataloged_instancejel:Q47Electrical and Electronic EngineeringCarbon creditEuropean unionEuropean Union AllowancesEngineering (miscellaneous)jel:Q49media_commonlcsh:TRenewable Energy Sustainability and the Environmentjel:Q0International economicsjel:Q4Emission Trading; European Union Allowances; Carbon MarketsKyoto ProtocolBusinessEmissions tradingFutures contractEnergy (miscellaneous)Energies
researchProduct

Prioritization of high-cost new drugs for HCV: making sustainability ethical

2016

Hepatitis C virus (HCV) infection is a major health problem worldwide. Chronic HCV infection may in the long run cause cirrhosis, hepatic decompensation and hepatocellular carcinoma, with an ultimate disease burden of at least 350,000 deaths per year worldwide. The new generation of highly effective direct acting antivirals (DAA) to treat HCV infection brings major promises to infected patients in terms of exceedingly high rates of sustained virological response (SVR) but also of tolerability, allowing even the sickest patients to be treated. Even in the face of the excellent safety and efficacy and wide theoretical applicability of these regimens, their introduction is currently facing cos…

Carcinoma HepatocellularHealth PrioritiesLiver NeoplasmsInterferon-alphaHepacivirusHepatitis C ChronicAntiviral AgentsHepatitis CDrug CostsSettore MED/02 - Storia Della MedicinaAccess to care cirrhosis Direct acting antivirals Distributive justice Ethics Hepatitis C Hepatocellular carcinoma PrioritizationSettore MED/43 - Medicina LegaleQuality of LifeAnimalsHumansDrug Therapy Combinationhepatitis C
researchProduct

Distribution, ecology, vegetation and conservation survey on the relictual population ofCarex panormitanaGuss. (Cyperaceae) in Sicily (Italy)

2013

We report the results of research on the Carex panormitana Guss. (Cyperaceae) population in Sicily, carried out within its locus classicus at the Oreto River (Palermo). The survey led to a morphological, biological and autoecological characterization, to the definition of the current distribution in the site, to an estimate of the number of individuals and to an analysis of its conservation status. The risk status was also assessed and the species was ascribed to the category Critically Endangered (CR), in accordance with the CR B1ab (ii, iii, v) and EN C1 IUCN criteria. Moreover, the phytosociological survey carried out on the meso-hygrophilous vegetation in which the species is dominant a…

Carexeducation.field_of_studyEcologybiologyCurrent distributionPhytosociologyEcologyphytosociologyPopulationForestryPlant Sciencecritically endangered speciebiology.organism_classificationHabitats Directive 92/43/EECCritically endangeredCarex panormitanapopulation analysisSettore BIO/03 - Botanica Ambientale E ApplicataIUCN Criteria and Direct ThreatIUCN Red ListConservation statusCyperaceaeCyperaceaeeducationEcology Evolution Behavior and SystematicsWebbia
researchProduct

Historia del duque Carlos de Borgoña, bisaguelo del Emperador Carlos Quinto / el secretario Aguilon

1586

Sign.: A-N8, O4 Retrat de Carles, duc de Borgonya a cavall en O4 Port. amb esc. grav. - Capll.

Carles I el Temerari Duc de Borgonya (1433-1477)
researchProduct